Navigation Links
BioSpecifics Technologies Corp. Reports Third Quarter 2012 Financial Results
Date:11/8/2012

LYNBROOK, N.Y., Nov. 8, 2012 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company developing first in class collagenase-based products marketed as XIAFLEX® in the U.S. and XIAPEX® in Europe and Eurasia, today announced its financial results for the third quarter ended September 30, 2012 and provided a corporate update.

"We are very happy with the ongoing clinical development progress for our XIAFLEX pipeline, including the recent submission of a sBLA filing by our partner Auxilium for the potential treatment of Peyronie's disease," said Thomas L. Wegman, President of BioSpecifics. "Additionally, Auxilium recently completed enrollment in its cellulite Phase Ib and frozen shoulder Phase IIa studies and began enrollment for its 600 patient label expansion study for Dupuytren's contracture patients with multiple palpable cords. We look forward to reporting top-line data from each of these studies in the fourth quarter of 2012, the first quarter of 2013 and the first half of 2014, respectively. We also anticipate that we will complete enrollment in our internally-managed human and canine lipoma Phase II trials during the first half of 2013. In addition, we are very encouraged by the ongoing commercial initiatives Auxilium has implemented to continue to expand XIAFLEX sales for Dupuytren's contracture in the U.S."

Third Quarter 2012 Financial Results
BioSpecifics reported net income of $0.5 million for the third quarter ended September 30, 2012, or $0.07 per basic and diluted common share, compared to a net income of $0.3 million, or $0.04 per basic and diluted common share, for the same period in 2011.

Total revenue for the third quarter of 2012 was $2.4 million, compared to $1.9 million for the same period in 2011.

Royalty, mark-up on cost of goods sold, and earn-out revenues for the third quart
'/>"/>

SOURCE BioSpecifics Technologies Corp.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. BioSpecifics Technologies Corp. To Present at UBS Global Life Sciences Conference
2. BioSpecifics Technologies Corp. Reports Second Quarter 2012 Financial Results
3. BioSpecifics Technologies Corp. Announces Presentations at Two Upcoming Investor Conferences in March
4. BioSpecifics Technologies Corp. Announces Appointment of George Gould to Board of Directors
5. Palatin Technologies Reports Positive Results for Phase 2B Bremelanotide Female Sexual Dysfunction Trial
6. Patient Safety Technologies Reports Third Quarter 2012 Results
7. Life Technologies Announces Third Quarter 2012 Results
8. Life Technologies Reschedules Issuance Of Third Quarter 2012 Performance Report And Associated Conference Call And Webcast to Thursday, November 1, 2012 Due To Expected Severe Weather Conditions
9. Life Technologies New State-of-the-Art Manufacturing Facility in China Provides Forensics Labs Rapid Access to World-Leading DNA Testing Solutions
10. $1 Million Global B.R.A.I.N. Prize Announced by Israel Brain Technologies
11. Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year End 2012 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... OAK RIDGE, Tenn., July 24, 2014 -- A novel ... at the Department of Energy,s Oak Ridge National Laboratory ... known for its unusual physical and electrochemical properties. ... examined how oxygen affects the surface of a perovskite ... electronic behavior. The new avenue to understand surface behavior ...
(Date:7/24/2014)... Security forces worldwide rely on sophisticated equipment, trained ... other public areas against terrorist attacks. A revolutionary ... about to make their job much easier. , ... Patolsky of Tel Aviv University ,s School of ... developed by the Herzliya company Tracense, picks up ...
(Date:7/24/2014)... DUBLIN , July 24, 2014 ... the "Global Cell Culture Market 2014-2018" report ... Cell culture is the in vitro ... such as research, cell studies, and biopharmaceutical production. Cell ... vaccine production. Cell culture instruments and cell culture consumables ...
(Date:7/24/2014)... Three companies from the angelMD network ... C Competition. Out of 700 competition entrants, Chiron Health, ... semi-final round. In this round twenty teams are invited ... with mentoring from thought-leaders and medical entrepreneurs from all ... angelMD commitment to the Livestrong vision around the Big ...
Breaking Biology Technology:ORNL study reveals new characteristics of complex oxide surfaces 2Nano-sized chip 'sniffs out' explosives far better than trained dogs 2Global Cell Culture Market 2014-2018: Key Vendors are Becton, Dickinson and Co, EMD, GE Healthcare, Lonza Group, Sigma Aldrich and Thermo Fisher Scientific 23 angelMD Startups Make Livestrong Big C Semi-finals 2
... Spherix,Incorporated (Nasdaq: SPEX ) reported a net ... The Company,s research and development costs,jumped to $5.9 million ... of,the Company,s Phase 3 clinical trial for Naturlose as ... trial is expected to last at least two years,and ...
... Meets LEEDS Standards for Sustainable Development, PLEASANTON, ... today announced the opening of its new research ... The,building represents the final phase of consolidation of ... which now houses close to 500,employees, including 120 ...
... Ratcliff, the,award-winning architecture, planning and interiors firm, ... care tower,accompanied by a 767-stall parking garage and ... - Walnut Creek Campus. The Thomas J.,and Muriel ... ground will add,230 private and six semi-private rooms, ...
Cached Biology Technology:Spherix Reports 2007 Financial Results 2Roche Molecular Diagnostics Invests $57.5 Million in 'Green' Research Building 2Roche Molecular Diagnostics Invests $57.5 Million in 'Green' Research Building 3Ratcliff Designs Hospital of the Future for John Muir Medical Center - Walnut Creek Campus 2Ratcliff Designs Hospital of the Future for John Muir Medical Center - Walnut Creek Campus 3
(Date:7/24/2014)... 24, 2014 -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) (the "Company") ... active control Phase 3 study of Zerenex (ferric citrate), ... the treatment of hyperphosphatemia in patients with end-stage renal ... and iRon delivery with FErric CiTrate in EsrD) was ... American Society of Nephrology ( JASN ). ...
(Date:7/24/2014)... numbers have decreased by 45% on average over a ... reports a study on the impact of humans on ... enormous benefits invertebrates such as insects, spiders, crustaceans, slugs ... and pest control for crops, decomposition for nutrient cycling, ... in Science and led by UCL, Stanford ...
(Date:7/24/2014)... the product of 3.5 billion years of evolutionary trial ... life. But it may be reaching a tipping point. ... analysis of data published in Science , an ... decline of animals is contributing to what appears to ... biological extinction event. , Since 1500, more than 320 ...
Breaking Biology News(10 mins):Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 2Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 3Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 4Invertebrate numbers nearly halve as human population doubles 2Invertebrate numbers nearly halve as human population doubles 3Stanford biologist warns of early stages of Earth's 6th mass extinction event 2Stanford biologist warns of early stages of Earth's 6th mass extinction event 3
... online citizen-science project launches called "Plankton Portal" ... Rosenstiel School of Marine and Atmospheric Sciences (RSMAS) in ... and the National Science Foundation (NSF) and developers at ... ocean from the comfort of your own home. You ...
... two typhoons over a three-week period in August, ... partnership with the Okinawa Institute of Science and ... OceanCube Observatory System in waters off Motobu Peninsula, ... to ecologically significant coral reefs. The observatory system ...
... research group from Singapore, scientists at University of Copenhagen ... of truncated O-glycans aid growth properties of cancer cells. ... significance of these truncated O-glycans, and therefore, the results, ... , represent an important contribution to understanding the growth ...
Cached Biology News:Online citizen scientists: Classify plankton images 2Establishing world-class coral reef ecosystem monitoring in Okinawa 2Establishing world-class coral reef ecosystem monitoring in Okinawa 3Specific sugar molecule causes growth of cancer cells 2
... Useful as a positive control for ... to chromatin in vivo is a crucial ... extent of crosslinking is probably the most ... subsequent immunoprecipitation step should be taken into ...
Mouse monoclonal [M2II-12] to MRP2 ( Abpromise for all tested applications). entrezGeneID: 1244 SwissProtID: Q92887...
The Programmable MP-5000P-F Power Supply can be applied for any Microfluidic application....
Rab GDP dissociation inhibitor beta...
Biology Products: